Insmed Incorporated

Company snapshot

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. We are dedicated to making a meaningful impact in patients’ lives as well as the communities where we live and work. Our team is guided by our core values of collaboration, accountability, passion, respect, and integrity. Insmed

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Insmed Incorporated. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Insmed Incorporated.

1. Jun 8, 2026 Clinical update

   The BiRCh Study — Phase 2

2. Jun 8, 2026 Clinical update

   INS1009-212 — Phase 3

3. Jun 8, 2026 Clinical update

   INS-416 — Phase 3

4. Jun 8, 2026 Clinical update

   INS1009-311 — Phase 3

5. Jun 8, 2026 Clinical update

   INS1009-203 — Phase 3

View all clinical trial activity →

• What is Insmed Incorporated?

  Insmed is a pharma organization headquartered in GB. Primary therapeutic focus areas include Pulmonary Hypertension Associated with Interstitial Lung Disease, Pulmonary Arterial Hypertension, Chronic Rhinosinusitis without Nasal Polyps (CRSsNP), Hidradenitis Suppurativa. NovaPhar

• Is Insmed Incorporated publicly traded?

  Insmed Incorporated appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Insmed Incorporated develop or market?

  We link 18 drug profile(s) where Insmed Incorporated is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/insmed-limited#company-drugs.

• What are the latest developments for Insmed Incorporated?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Insmed Incorporated focus on?

  Insmed Incorporated focuses on Pulmonary Hypertension Associated with Interstitial Lung Disease, Pulmonary Arterial Hypertension, Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) based on our analysis of their pipeline programs and drug development activities.